Formulation Development
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Neurona Therapeutics recently announced plans to initiate the Phase 3 EPIC clinical trial for its lead product candidate, NRTX-1001. NRTX-1001 is the first investigational human cell…
Phoenix Molecular Designs Dosed First Patient in Dauntless-1, a Phase 2 Clinical Trial of PMD-026 in Combination with Fulvestrant for RSK2-high Breast Cancer
Phoenix Molecular Designs recently announced the dosing of the first patient in their Phase 2 clinical trial, Dauntless-1. The Dauntless-1 trial will evaluate the therapeutic potential…
Tiziana Life Sciences Announces Agreement for Product Development Services With Renaissance Lakewood
Tiziana Life Sciences, Ltd. recently announced a product development services agreement with Renaissance Lakewood LLC, a leading Contract Development and Manufacturing Organization (CDMO) focused on…
Medigene AG Expands Patent Portfolio With Patent Grant for its JOVI Technology in the US
Medigene AG recently announced it has been issued a patent by the US Patent Office protecting its JOVI technology, a method allowing the enrichment of…
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. recently announced new translational data from ongoing analyses of results from the Company’s Phase 2 OVATION 2 Study of IMNN-001, its investigational interleukin-12 (IL-12)…
Atrandi Biosciences Raises $25M Series A Led by Lux Capital to Drive the Future of Single-Cell Multiomics with Semi-Permeable Capsule Technology
Atrandi Biosciences recently announced a $25 million Series A funding round led by Lux Capital, with participation from Vsquared Ventures, Practica Capital, Metaplanet and GRIDS Capital.…
Silo Pharma Expands Intellectual Property Portfolio With Provisional Patent
Silo Pharma, Inc. recently announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.…
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex
Artelo Biosciences, Inc. recently announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings were presented by Professor Saoirse…
IN8bio Presents Positive Phase 1 Data Highlighting Durability of Remissions in High-Risk AML
IN8bio, Inc. recently presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in…
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Bicara Therapeutics Inc. recently announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab…
Abcuro Announces $200 Million Financing to Advance its First-In-Class Medicine in Development for Inclusion Body Myositis
Abcuro, Inc. recently announced the closing of a $200-million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and…
Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology
Mangoceuticals, Inc. recenntly announced it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian…
MediWound Initiates the VALUE Global Phase 3 Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
MediWound Ltd. recently announced the initiation of VALUE, a global, pivotal Phase 3 trial evaluating EscharEx for the treatment of venous leg ulcers (VLUs). “We…
LEADERSHIP PANEL - What Will Have the Most Impact on Drug Development in 2025?
Contributor Cindy H. Dubin asked several life science leaders what they believe will have the greatest impact on drug development in 2025.
FORMULATION FORUM - Nanoparticle Technologies for Oral Delivery of Peptides & Proteins
Jim Huang, PhD, and Shaukat Ali, PhD, examine various nanoparticle technologies in oral delivery of large molecules.
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety & Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Silo Pharma, Inc. recently announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods…
MICRONEEDLE MANUFACTURING - The Value of a Manufacturing-Oriented Microneedle Mindset
Andrew Riso says despite the significant buzz surrounding microneedle technology, a considerable gap remains between innovations and market-ready products. While early stage development and preclinical studies have shown promising results, the challenge of translating these advancements into scalable, commercially viable products persists.
EXECUTIVE INTERVIEW - Resilience Rising: Advancing Therapies That Transform Lives
Dr. Susan Billings, Chief Commercial Officer of Resilience, discusses pressing issues in the CDMO space, the opportunities driving innovation, and how her company is shaping the future of drug substance and drug product manufacturing.
DRUG DEVELOPMENT - What is Formulation Development & Why is it Important?
Rob Holgate, PhD, and Nicola Watts, PhD, explain how this process involves a delicate balance of scientific rigor and practical application, and not only requires a profound understanding of the drug’s properties, but also the ability to navigate the many challenges of delivering the drug in an effective and patient-centric manner.
EXECUTIVE INTERVIEW - Lifecore Biomedical: Capacity to Keep Pace With Biologics Growth
Drug Development & Delivery recently interviewed Thomas Guldager, Vice President, Operations at Lifecore. With a 40+ year regulatory track record, Lifecore is a fully integrated CDMO with highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceuticals, including 20+ commercial products.
